An Illustrated History of Science Denial

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Infographic | August 23, 2021

As per the study, the global Bioinformatics market was valued at $3.4 billion in 2013, and it is expected to reach $12.8 billion by 2020. The market is expected to grow at a CAGR of 21.2% during 2014-2020

Infographic | April 13, 2020

Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.

Infographic | August 12, 2022

The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.

Infographic | April 7, 2020

CRISPR Integration: CRISPR/Cas9 System for insertion in eukaryotic cells Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA. CRISPR-chrom: Improves access to the genome so that CRISPR-driven edits can be done more efficiently.

Infographic | August 5, 2021

Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.